Wegovy Weight Loss Calculator
Project your expected weight loss based on STEP clinical trial data
Medical Disclaimer: This tool provides general educational estimates. Always consult your prescribing physician or healthcare provider before making medication changes or interpreting results from population-based models.
Frequently Asked Questions
In the STEP 1 clinical trial (N=1,961), participants taking Wegovy (semaglutide 2.4 mg weekly) lost an average of 14.9% of their body weight over 68 weeks.
Both contain semaglutide, but Wegovy is FDA-approved for chronic weight management at 2.4 mg weekly, while Ozempic is approved for type 2 diabetes at up to 2.0 mg weekly.
Yes. In 2025, the FDA approved oral semaglutide for chronic weight management. The OASIS clinical trials showed approximately 15% weight loss at 68 weeks.
The STEP 4 trial showed participants who switched to placebo regained approximately two-thirds of lost weight over 48 weeks.
Yes. Projections are derived from the STEP and OASIS clinical trial programs.
Sources
Methodology
This calculator projects weight loss using STEP and OASIS clinical trial data. For injectable Wegovy (2.4 mg weekly), projections are based on STEP 1 (14.9% at 68 weeks). For oral Wegovy (50 mg daily), OASIS data (~15% at 68 weeks). A non-linear logarithmic curve models the clinical pattern. Activity level adjustments modify the projection by up to +/-10%.
Wegovy (semaglutide 2.4 mg) produced 14.9% average weight loss at 68 weeks in STEP 1 (N=1,961). Oral Wegovy (50 mg daily) achieved ~15% at 68 weeks in OASIS trials.
What else do you want to know?
Ask Pulse anything.